CAR-T cell therapy: cytokine release syndrome (CRS)
Evidence-based neurology checklist on car-t cell therapy: cytokine release syndrome (crs): Pathology CRS usually develops 2-3 days after infusion but can be delayed up to 14 days It progresses over hours to days The severity is graded 1-4 Clinical features Laboratory features: elevated indices…
Pathology
- CRS usually develops 2-3 days after infusion but can be delayed up to 14 days
- It progresses over hours to days
- The severity is graded 1-4
Clinical features
Laboratory features: elevated indices
Complications
Treatment
Acronym
References
- Freyer CW, Porter DL. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J Allergy Clin Immunol 2020 (Online ahead of print).
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019; 34:45-55.
